Lassila & Tikanoja (LASTIK) CMD 2025 summary
Event summary combining transcript, slides, and related documents.
CMD 2025 summary
27 Feb, 2026Strategic direction and demerger rationale
Planned demerger will create two standalone businesses, Lassila & Tikanoja and Luotea, each with 100% ownership by current shareholders, aiming to improve performance, accelerate growth, and enhance transparency for shareholder value.
Shareholders will receive shares in both entities, with trading of new shares starting January 2, 2026.
Timeline includes approval in August 2025, EGM in December, and completion by year-end 2025.
Focus is on creating a pure-play circular economy leader in the Nordics, leveraging a unique end-to-end platform.
The company targets increased management focus and more efficient capital allocation post-demerger.
Market position and business model
Holds a leading market share in Finland (~20%) and a growing presence in Sweden, with strong positions in hazardous waste and industrial services.
Net sales in 2024 were EUR 424 million, with adjusted EBITDA of EUR 86 million (20% margin) and EBITA of EUR 44 million (10%+ margin).
Operates across waste management, hazardous waste, remediation, industrial services, and water treatment.
End-to-end service offering covers the full waste-to-value cycle, providing a competitive advantage.
68–84% of revenue comes from long-term contracts, ensuring resilience and predictability.
Growth strategy and financial targets
Targets over 6% average annual sales growth and an 11% EBITA margin in the midterm (3–5 years).
Growth pillars: cross-selling/upselling, geographic expansion in Sweden, and deeper integration in the value chain (waste-to-material/product, remediation).
Plans to support growth with organic investments, selective bolt-on acquisitions, and disciplined M&A.
Maintains a strong balance sheet, with a dividend policy of at least 50% of net income and net debt/EBITDA at 1.9x.
Free cash flow of EUR 40 million annually enables both growth investments and shareholder returns.